522 related articles for article (PubMed ID: 35650449)
1. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
Mahapatra MK; Karuppasamy M; Sahoo BM
Pharm Res; 2022 Jun; 39(6):1233-1248. PubMed ID: 35650449
[TBL] [Abstract][Full Text] [Related]
2. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS;
J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043
[TBL] [Abstract][Full Text] [Related]
3. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
[TBL] [Abstract][Full Text] [Related]
4. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
Barritt AS; Marshman E; Noureddin M
Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
[TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
Patel Chavez C; Cusi K; Kadiyala S
J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
[TBL] [Abstract][Full Text] [Related]
6. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.
Mahapatra MK; Karuppasamy M; Sahoo BM
Rev Endocr Metab Disord; 2022 Jun; 23(3):521-539. PubMed ID: 34993760
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
Nowell J; Blunt E; Gupta D; Edison P
Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
[TBL] [Abstract][Full Text] [Related]
8. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
9. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
Abdelmalek MF; Harrison SA; Sanyal AJ
Diabetes Obes Metab; 2024 Jun; 26(6):2001-2016. PubMed ID: 38511418
[TBL] [Abstract][Full Text] [Related]
10. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
12. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.
Goldenberg RM; Gilbert JD; Manjoo P; Pedersen SD; Woo VC; Lovshin JA
Obes Rev; 2024 Mar; 25(3):e13663. PubMed ID: 37968541
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
[TBL] [Abstract][Full Text] [Related]
14. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
Kopp KO; Glotfelty EJ; Li Y; Greig NH
Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
[TBL] [Abstract][Full Text] [Related]
16. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus
Miyasaka K
Nihon Yakurigaku Zasshi; 2022; 157(2):146-154. PubMed ID: 35228448
[TBL] [Abstract][Full Text] [Related]
17. Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
Bandyopadhyay I; Dave S; Rai A; Nampoothiri M; Chamallamudi MR; Kumar N
Curr Drug Targets; 2022; 23(3):311-327. PubMed ID: 34468297
[TBL] [Abstract][Full Text] [Related]
18. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
19. Practical guidance for use of oral semaglutide in primary care: a narrative review.
Morales J; Shubrook JH; Skolnik N
Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW
Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]